Piper Jaffray analyst Danielle Brill raised her price target for GW Pharmaceuticals to $210 from $185 after Epidiolex sales in Q1 of $33.5M "solidly beat" her $20.7M estimate. Epidiolex's growth trajectory will continue over the coming quarters given expected launch in Europe, ongoing dose-titrations, increasing penetration into adult population, transition of remaining expanded access program patients to commercial product, and expansion into new indications, Brill tells investors in a research note. She expects GW's momentum to continue and reiterates an Overweight rating on the shares.